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Abstract
Background: Implementation of yellow fever vaccination is currently hampered by limited supply of vaccine. An alternative
route of administration with reduced amounts of vaccine but without loss of vaccine efficacy would boost vaccination
programmes.
Methods and Findings: A randomized, controlled, non-inferiority trial was conducted in a Dutch university center between
August 2005 and February 2007. A total of 155 primary vaccinated and 20 previously vaccinated volunteers participated.
Participants were randomly assigned in a 1:1 ratio to receive intradermal (i.d.) vaccination with live attenuated yellow fever
17D vaccine at a reduced dose (1/5th; 0?1 mL) or the conventional subcutaneous (s.c.) vaccination (0?5 mL). Antibody
neutralization titers were determined at 2, 4 and 8 weeks and 1 year after vaccination by counting the reduction in virus-
induced plaques in the presence of serial serum dilutions. Adverse events were documented in a 3-week dairy. Viraemia was
measured 5 days after vaccination. From 2 weeks up to one year after vaccination, the maximum serum-dilution at which
80% of the virus plaques were neutralized, which indicates protection against yellow fever, did not differ between those
given a reduced i.d. dose or standard s.c. dose of vaccine. In all cases the WHO standard of seroprotection (i.e. 80% virus
neutralization) was reached (in 77/77 and 78/78, respectively). Similar results were found in the previously vaccinated
individuals. Viraemia was detected in half of the primary vaccinated participants, which was not predictive of serological
response. In revaccinees no viraemia was detected.
Conclusions: Intradermal administration of one fifth of the amount of yellow fever vaccine administered subcutaneously
results in protective seroimmunity in all volunteers. Albeit this vaccination route should enable vaccination of five-times as
many individuals at risk for disease, these results should now be confirmed in field studies in areas with potential yellow
fever virus transmission to change vaccination policy.
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Introduction
Yellow fever is a re-emerging viral hemorrhagic febrile illness in
tropical and sub-tropical areas of Africa and remains a major health
threat in South-America. It is estimated to affect 200.000 individuals
annually of whom approximately 30.000 die worldwide [1]. The
virus is transmitted by infected Aedes mosquitoes, and may cause a
wide spectrum of disease, from mild symptoms to severe illness
accompanied by fever, hepatic and myocardial injury, renal failure,
hemorrhage, and even death. There is no curative treatment for
yellow fever, making vector control and vaccination essential
ingredients in the prevention of yellow fever morbidity andmortality.
Although this flavivirus has never emerged in Asia, the Asian
continent is considered vulnerable to future introduction of the
virus, because of the presence of a large susceptible human
population, the presence of the urban vector and increasing
international travel [2]. Also Western countries may be at risk:
for instance, in the Netherlands, the Aedes albopictus mosquito
was introduced via imported bamboo from China, and its
capability of transmission of flaviviruses is currently under
investigation.
Thus, there is a potential risk for large epidemics of urban
yellow fever now that migration of people from rural areas may
introduce the virus into areas of high human population density,
such as large African and South-American cities. During yellow
fever epidemics in non-immune populations, case-fatality rates
may be as high as 50% [3]. In case of simultaneous outbreaks in
megacities the current emergency stockpile of yellow fever vaccine
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of 6 million doses will not be sufficient to protect the large
populations from the disease [4].
Yellow fever vaccination is the single most important and
effective means to prevent the occurrence of yellow fever, and
carries a low risk of serious adverse events. The live-attenuated
17D vaccine provides protective immunity within one to two
weeks in 95% of those vaccinated [5]. The World Health
Organization (WHO) therefore strongly recommends to include
yellow fever vaccination in at-risk countries, as part of the routine
childhood immunization program. However, hampered by a
limited vaccine supply, this recommendation has not yet been
acted upon as epidemic emergencies have priority. Besides mass
immunization campaigns in response to epidemic outbreaks and
planned routine childhood immunization programmes, yellow
fever vaccination is used for preventive immunization of travellers
to endemic regions [6]. Therefore, to circumvent the consequence
of current shortage of vaccine supplies, there is an urgent need to
find alternatives for the current standard of yellow fever
vaccination, i.e., the subcutaneous administration of 0?5 mL
17D vaccine.
In general, the route of administration of a particular vaccine,
e.g., intramuscular, subcutaneous or intradermal, appears to have
been reached at arbitrary historical grounds. For the yellow fever
vaccine, subcutaneous administration of 0?5 mL followed the
initial human trials in which yellow fever 17D (YF217D) vaccines
were first put to extensive use. However, for some vaccines
already, for instance rabies, hepatitis B and influenza vaccines, the
classical subcutaneous or intramuscular routes have been
challenged by the apparent efficacy of intradermal administration
using appreciably smaller amounts of vaccine [7–10]. The safety
and efficacy of this route of administration has not been addressed
for the yellow fever vaccine. Interestingly, already in 1943, at the
dawn of yellow fever vaccine development, Fox and colleagues
observed an immune response after intradermal administration of
the YF217D vaccine [11]. However, the population investigated
was small and the method used to assess antibody responses is
irreconcilable with current definitions of seroprotection formulat-
ed by the WHO. Furthermore, scarification experiments with
yellow fever vaccine conducted in the 1950s revealed a lower
response rate when compared to subcutaneous inoculation
[12,13].
In this study we investigate the efficacy of intradermal
inoculation of yellow fever vaccine at one fifth the amount given
subcutaneously, as a potential strategy to reduce costs and increase
vaccine coverage in areas with limited amounts of vaccine
available for mass vaccination as well as for travellers to these
areas. Furthermore, to elucidate requirements for the induction of
an effective immune response to yellow fever vaccination we
assessed antibody responses in relation to post-vaccination
viraemia in both primary and revaccinated individuals.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see checklist S1 and
protocol S1 with amendments S2, S3 and S4.
Objectives
This study was conducted to determine whether reduced dose
i.d. yellow fever vaccination (1/5th; 0?1 mL) would be as
efficacious and safe as the conventional s.c. vaccination
(0?5 mL). Efficacy of vaccination was measured by virus
neutralization plaque reduction assay.
Study design and Participants
Healthy volunteers of 18 years and older were eligible for
inclusion. We excluded volunteers with a compromised immunity
due to underlying illness or immunosuppressive medication,
pregnant volunteers and those with chicken egg allergy. The
study was carried out between August 2005 and February 2007.
Subjects were randomly assigned by the investigator (AHR) to
either receive intradermal (i.d.) (experimental vaccination group)
or subcutaneous (s.c.) (conventional vaccination group) yellow
fever vaccination. Randomization was performed with the use of
sealed envelopes containing the vaccination code balanced
through in permuted blocks of 10 each. Vaccinations were
administered at the travel clinic of the LUMC by the investigators
who were trained in both methods of vaccine administration.
In the experimental vaccination group, participants received
0?1 mL YF217D vaccine intradermally on the dorsal side of the
right forearm. The syringe which was used for i.d. administration
is identical to the syringe used for administration of tuberculin in
the Mantoux test. The quality of the i.d. injection was defined by
the diameter of the arisen cutaneous wheal (adapted from the
tuberculin skin test) [14], with 6 mm being the lowest acceptable
diameter. The conventional vaccination group received 0?5 ml
YF217D vaccine subcutaneously in the right upper deltoid region.
17D Yellow Fever Vaccine. The live, attenuated, 17D
vaccine used in this study was manufactured on embryonated
chicken eggs according to WHO regulations and stored according
to manufacturer’s guidelines. All administered vaccines originated
from the same vaccine lot (Stamaril, Lot no Y5597, Sanofi Pasteur,
France). A single vaccination dose of 0?5 ml contained
approximately 3?56104 plaque forming units (PFU), measured
in two randomly selected vials. Multiple dosages (maximally 4)
were obtained from one vial for i.d. vaccination. After
reconstitution, vials were stored at 4uC and discarded after
maximally 4 hours.
Procedures
Data collection. At the time of inclusion, data on
demographic and clinical characteristics of the participants were
obtained, including information on possible flavivirus exposure
(defined as travel to a flavivirus endemic country) in the 5 years
prior to entering the study and previous yellow fever vaccination.
Blood samples were collected in all (155) primary vaccinated
participants before vaccination, and 4 and 8 weeks after
vaccination. An additional blood sample was collected 2 weeks
after vaccination in 55 primovaccinees (the last 55 consecutive
subjects entering the study) to investigate the kinetics of the
neutralizing antibody response in more detail.
Extra ethylenediamine tetraacetic acid (EDTA) blood samples
were collected 5 days after vaccination in the first 24 consecutive
primovaccinees entering the study.
In 20 previously vaccinated participants blood was drawn
before vaccination, and 5 days and 2 weeks after booster
vaccination (figure 1). Approximately one year after vaccination,
one additional blood sample was taken from all participants who
could be contacted (96 participants). A financial compensation was
given for every blood sample collection at completion of the study.
None of the participants withdrew prematurely.
Participants were asked to document clinical symptoms (local and
systemic) after vaccination in a three-week diary. Solicited symptoms
were; erythema, pain and swelling at the site of injection, fever and
myalgia. Severity of adverse events was documented as – (absent), +/
2 (mild), + (moderate) and ++ (severe).
Constant virus – varying serum dilution Plaque
Reduction Neutralization Test (PRNT). The tests were
Intradermal YF-17D Vaccination
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carried out in 6-well plates (Corning Inc., USA) using a slightly
modified technique described originally by De Madrid and
Porterfield [15]. Briefly, approximately 66105 Vero cells/mL
were seeded per well in 62well plates and cultured to obtain a
confluent monolayer. Sera were complement inactivated at 56uC
for 1 hour. Prevaccination sera were tested in 1:16 dilution, to
which 100 PFU of 17D-YF were added. Postvaccination sera were
tested in two-fold dilutions starting from 1:16 to 1:512. 100 PFU
YF217D virus were added to each serumdilution. All test sera
were assayed in duplicate. After 1 hour incubation on ice, the
mixtures of virus and serum were added to the Vero cell
monolayers and incubated for 1 hour at 37uC. An overlay of 26
DMEM and 2% agarose was added. After 5 days of incubation at
37uC, the overlay was discarded and cell monolayers were stained
with crystal violet. Plaques were counted by eye. Virus
neutralization (VN) was calculated for each serum dilution (i)
with the following formula: VN(i) = 1006 (number of PFU in
diluted postvaccination serum/number of PFU in pre-vaccination
serum (in a 1:16 dilution)). For comparison of i.d. and s.c.
vaccination, serum dilution at which log10 neutralization index 0?7
(80% VN) occurred was taken as endpoint, as this corresponds to
the generally accepted definition of protection [16].
Reverse Transcriptase-Polymerase Chain Reaction (RT-
PCR). RT2PCR of YF217D was performed at the department
of Virology of the Erasmus Medical Center according to Nijhuis
and colleagues [17]. Briefly, viral RNA was isolated and reverse
transcribed (Taqman Reverse Transcription Reagents, Applied
Biosystems International). cDNA synthesis was performed in a J
Mini Gradient Thermal Cycler (BioRad, Netherlands) for real-
time PCR, the following YF specific primers and probe were used
[18]:
YFV-1 (forward) AATCGAGTTGCTAGGCAATAAACAC
YFV-2 (reverse) TCCCTGAGCTTTACCAGA
YFV-P (probe) FAM-ATCGTTGAGCGATTAGCAG-BHQ
with FAM (62carboxyfluorescein) as 59-reporter dye and BHQ
(Black Hole Quencher) as the 39-quencher dye. Real-time PCR
was monitored on ABI Prism 7500 Seq. Detection System
(Applied Biosystems International). Cycle threshold (Ct) values
were used to compare viraemia in i.d. and s.c. groups
quantitatively.
Ethics
The protocol and consent forms were approved by the Medical
Ethical Committee of the Leiden University Medical Center
(LUMC), the Netherlands (ISRCTN46326316). Written informed
consent was obtained from each participant.
Statistical methods
Power calculations for primovaccinees were based on a one-
sided non-inferiority according to Armitage P., et al. [19], formula
18.5, with a maximally acceptable difference (d) of 0?04 between
the experimental and conventional vaccination group, a of 0?05, b
of 0?2 and a p (overall probability of positive response) of 0?99 [5],
which makes s2 = 0?0099. The number of participants needed to
confirm non-inferiority of low dose i.d. vaccination under these
assumed conditions are 77 per group. For the antibody response in
previously vaccinated individuals receiving a booster vaccination,
basic descriptive statistics are used. It was anticipated that the
small number in this subgroup would not allow a definite
conclusion concerning non-inferiority and no power calculation
Figure 1. Flow chart of study participants. Included study participants from August 2005 until February 2007. PV =post vaccination.
RT2PCR=Reverse transcriptase polymerase chain reaction. Wks =weeks and yr = year.
doi:10.1371/journal.pone.0001993.g001
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was performed. Twenty previously vaccinated persons were
included to monitor possible trends in interference of neutralizing
antibodies in yellow fever vaccination. Paired t-test was performed
to calculate their increase in neutralization after booster
vaccination and linear regression was used to calculate influence
of circulating antibodies on booster vaccination. Neutralizing
capacity of sera after i.d. and s.c. vaccination were compared with
Student’s t-test. Where appropriate, Chi-square tests were used,
and Wilcoxon’s test for non-parametrical distributed numerical
data. Statistical analysis was performed using a computer-assisted
software package (SPSS version 12.0, SPSS Inc., Chicago, IL).
Results
Study population
We enrolled 175 volunteers from August 2005 to February 2007
(figure 1). Baseline characteristics of the study population are given
in table 1.
Concerning the accuracy of i.d. vaccine delivery, the mean
diameter of the cutaneous wheal measured after vaccination was
8 mm (range 6–10 mm), indicating that all (N= 87) i.d. vaccina-
tion wheals met the minimal requirement for acceptable size.
Vaccine efficacy
Four weeks after vaccination, 80% virus neutralization (VN) at
the least diluted serum (dilution of 1:16) was achieved by 77 of 77
of the intradermally and by 78 of 78 of the subcutaneously
vaccinated primovaccinees. The percentage of VN in both study
groups was linearly correlated to serum dilution at all time points
measured (data not shown). Ninety percent neutralization was
achieved by 70 of 77 (91%) and by 69 of 78 (89%), respectively.
Plotting of neutralization indices against serum dilution showed
similar kinetics of i.d. and s.c. vaccination at all measured time
points (data not shown). This allowed us to compare the serum
dilution at which 80% of yellow fever was neutralized, which is
similar in both groups at all time points measured (figure 2).
No difference in percentage of virus neutralization was
measured in either (i.d. or s.c.) group between male and female
participants, nor between recent travel to flavivirus endemic
countries or not (data not shown).
Neutralizing capacity of 1:16 diluted prevaccination serum of
previously vaccinated participants ranged from 2% to 97%
reflecting the wide range of years since their last YF vaccination
(0?5 to 18 years). The mean percentage of VN by the least diluted
serum before vaccination in the i.d. group was 77% (range 51%–
97%) and in the s.c. group was 74% (range 2%–97%). All
revaccinees reached protective neutralization immunity 2 weeks
(19/19) and 1 year (15/15) after vaccination.
Both the i.d. and the s.c. group of revaccinated participants
showed a significant rise in VN after booster vaccination. The
mean increase in percentage of neutralization by serum (dilution
1:16) before and 2 weeks after vaccination in the i.d. vaccinated
participants was 18% (95% CI; 8%–28%) and 20% (95% CI; 4%–
36%) in the s.c. group (data not shown). To investigate the
influence of prevaccination neutralizing antibody titer on post-
vaccination VN, pre- and post vaccination serum dilutions at
which 80% VN occurred were plotted (figure 3). In linear
regression analysis, an increase in postvaccination VN correlated
significantly with a higher prevaccination antibody titer (coefficient
0.54, p= 0?02). Thus, the presence of circulating neutralizing
antibodies in this population did not inhibit a booster response.
Viraemia was measured by RT-PCR 5 days after vaccination in
24 primovaccinees and all revaccinees (N= 20). In the latter no
YF-17D RNA was detected in the blood. The percentage of
primary vaccinated subjects positive for YF virus detection was
comparable in the i.d. (7 of 13, 54%) and s.c. (5 of 11, 45%) group,
as were the mean Cycle threshold (Ct) values (35?86 cycles and
37?52 cycles, respectively).
No difference was measured in the serum dilution at which 80%
VN occurred 4 weeks after vaccination between those with and
those without viraemia, irrespective of the route of vaccine
administration (figure 4).
Vaccine safety
Participants reported duration and severity of adverse events
after yellow fever vaccination in a 32week diary. In primary
vaccinated participants i.d. vaccination evoked redness and
swelling at the site of inoculation more frequently and for a
significantly longer period than after s.c. vaccination (p,0?001).
Itching at the site of injection was also reported more by i.d.
vaccinated primovaccinees (p = 0?02). The s.c. vaccinated primo-
vaccinees reported significantly longer pain at the site of injection
(p = 0?03), and more s.c. primary vaccinated participants reported
myalgia (p,0?01) (table 2). In previously vaccinated participants, a
similar trend of adverse events was monitored except for myalgia.
The severity of adverse events due to vaccination, which was
reported on a 4-level scale (2, +/2, +, ++), did not reveal a
difference in experienced discomfort (both local and systemic)
between the i.d. and s.c. group. Of the reported adverse events, 2/3rd
was experienced as mild (+/2) and 1/3rd as moderate (+). No i.d.
vaccinated and 3 s.c. participants rated their events as severe (++).
Discussion
Intradermal administration of 1/5th of the conventional yellow
fever vaccine dose was non-inferior to standard subcutaneous
Table 1. Comparability of intradermally and subcutaneously vaccinated groups
Participants Vaccine administration p-value
Intradermal Subcutaneous
Primovaccinees (N = 155) N Female (%) 56 (73) 65 (83) 0?1
Mean age (range) 27 (18–61) 25 (19–70) 0?2
Flavivirus$ N yes (%) 33 (43) 26 (33) 0?3
Revaccinees (N = 20) N Female (%) 7 (70) 8 (80) -
Mean age (range) 30 (20–50) 34 (21–48) 0?4
Age and gender distribution in primary (77 i.d., 78 s.c.) and booster (10 i.d., 10 s.c.) vaccinated populations. YF-17D = yellow fever vaccine virus.
$Flavivirus = possible flavivirus encounter in past five years defined as travelled to flavivirus endemic destination.
doi:10.1371/journal.pone.0001993.t001
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vaccination of the full dose as far as protective immune response and
safety is concerned: at 2, 4 and 8 weeks after administration, as well
as one year later, the titers of yellow fever-neutralizing antibodies
were identical in individuals being primary vaccinated intradermally
or subcutaneously. Both i.d. and s.c. administration of the vaccine
resulted in protective seroimmunity in all subjects. Finally, the
kinetics of the immune response were similar in both groups with
neutralizing antibody responses peaking at 4 weeks after vaccination.
Several aspects of this study require comment. First, assuming
99% seroprotection after primary vaccination in both groups, the
population size in this study does not allow to detect differences
less than 4% between the experimental (i.d.) and conventional
(s.c.) vaccination groups. However, the numbers are sufficient to
reliably measure a log 0?7 virus neutralizing capacity in at least
95% of those vaccinated intradermally, which meets the minimal
required percentage of seroprotection after vaccination, as defined
by the WHO [20]. Second, the viral dose contained in the trial
vaccine was 3?56104 PFU/0?5mL, which is equivalent to
approximately 56103 Mouse Lethal Dose (MLD)50 (21). A fivefold
reduction of vaccine dose for i.d. delivery then still contains the
minimal potency requirement (16103 MLD50) as defined by the
WHO [20], meaning that the results of this study cannot exclude
that s.c. vaccination with 0?1 mL dose might be protective. Several
lines of evidence however suggest that this may not be the case.
More than sixty years ago Fox and colleagues verified the
protective efficacy of human serum from vaccinees in a mouse
Figure 2. Protective virus neutralization after intradermal or subcutaneous vaccination against yellow fever. Comparison of reciprocal
serum dilutions at which 80% of yellow fever virus is neutralized in constant virus – varying serum dilution test after intradermal and subcutaneous YF
vaccination in primary vaccinated participants (n = 155). Bars represent 95% Confidence Intervals (CI). Virus neutralizing capacity of serum in both
groups was performed at similar time points but indicators are juxtaposed for visual enhancement. VN= virus neutralization.
doi:10.1371/journal.pone.0001993.g002
Figure 3. Pre- and post vaccination virus neutralizing capacity of serum of previously vaccinated participants. Pre- and
postvaccination (2 weeks) serum dilutions at which 80% VN occurred in previously vaccinated participants. When 80% VN was not reached by the
least diluted serum (1:16), samples were defined as ,16 (reciprocal serum dilution). VN=Virus neutralization.
doi:10.1371/journal.pone.0001993.g003
Intradermal YF-17D Vaccination
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challenge model and observed that at a similar vaccine dose, sera
from intradermally injected subjects were more efficacious than
sera of those injected subcutaneously [11]. Additionally, 0?1 mL
s.c. delivery of a live attenuated chimeric flavivirus vaccine against
Japanese encephalitis in non-human primates resulted in a 72fold
lower neutralizing antibody response compared to 0?1 mL i.d.
delivery by micro needle [22]. Finally, this study has been
performed in healthy adult volunteers who represent travellers to
and not individuals living in an area of potential yellow fever
transmission. This study should be repeated in a population living
in a yellow fever endemic area, to account for differences in skin
tissue composition, possible interactions by cross-reactive antibod-
ies against other flaviviruses, and possible decreased immune
response due to malnutrition or chronic parasitic infections.
Figure 4. Virus neutralizing capacity of YF-RNA negative and positive sera. Comparison of reciprocal serum dilutions, of serum obtained
4 weeks after vaccination, at which 80% VN occurred between positive and negative YF-17D RNA detection by RT-PCR in primary vaccinated
participants (N = 24). Bars represent the median reciprocal serum dilution. VN=Virus neutralization.
doi:10.1371/journal.pone.0001993.g004
Table 2. Solicited adverse events after primary and booster YF-17D vaccination.
Adverse event Primary vaccination (N=155) Booster vaccination (N=20)
Intradermal Subcutaneous Intradermal Subcutaneous
Local Erythema N yes (%) 63 (82) 25 (32) 6 (60) 1 (10)
Mean N days (s.e.m.) 4?3 (60?5) 1?1 (60?2) 3?2 (61?0) 1?0 (60?9)
Swelling N yes (%) 52 (68) 9 (12) 6 (60) 0 (0)
Mean N days (s.e.m.) 2?6 (60?4) 0?3 (60?1) 2?6 (60?9) -
Pain N yes (%) 6 (8) 15 (19) 2 (20) 0 (0)
Mean N days (s.e.m.) 0?1 (60?06) 0?6 (60?2) 0?2 (60?1) -
Severity N +/2 (mild) 39 15 3 -
N + (moderate) 24 9 2 2
N ++ (severe) - 1 -
Systemic Myalgia N yes (%) 12 (16) 27 (22) 1 (10) 1 (10)
Mean N days (s.e.m.) 0?4 (60?1) 0?7 (60?1) 0?1 (60?1) 0?7 (60?7)
Fever N yes (%) 4 (5) 8 (10) 0 (0) 0 (0)
Mean N days (s.e.m.) 0?1 (60?03) 0?2 (60?06) - -
Severity N +/2 (mild) 9 17 - -
N + (moderate) 3 8 1 1
N ++ (severe) - 2 - -
Safety of vaccination expressed in various parameters. Severity of adverse events could be graded with - (absent), +/2 (mild), + (moderate) and ++ (severe).
S.e.m. = standard error of the mean.
doi:10.1371/journal.pone.0001993.t002
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In regard to the reproducibility of these results, the significant
variation in viral load between YF-17D vaccine batches is of
importance. The batches generally contain 5–50 times the minimal
required potency dose to account for possible loss during storage and
transportation [5]. The YF-17D batch used in this study contained
five times the minimal required potency dose, and is therefore at the
low side of the batch-variability in viral vaccine load. Intradermal
YF-17D vaccination with other batches will thus yield similar results,
as no other batch is likely to contain less virus particles.
Correct i.d. vaccination is technically more demanding than
subcutaneous or intramuscular vaccination. By introducing a
minimal diameter cutoff of the cutaneous wheal following i.d.
vaccination, we allowed to control for proper i.d. delivery of the
vaccine. To our opinion, this simple test is a valuable tool to ensure
correct i.d. vaccination.
Local adverse events such as erythema and swelling were
reported to occur longer in the i.d. vaccinated group. This is
consistent with other intradermally administered vaccines [7,8],
and might represent the inflammatory reaction due to activation of
local immunomodulating cells. To our opinion this increased
duration of local adverse events will not be a reason to renounce
the new cost-effective method of yellow fever vaccination
investigated, as they were not experienced as more severely than
the adverse events in the s.c. group. Evidently, adverse events with
a frequency beneath 1/77 after low dose i.d. vaccination could not
be detected in this study.
The participants who had been previously vaccinated against
yellow fever all showed seroprotection after booster vaccination,
irrespective of their pre-booster VN capacity, implying that
circulating neutralizing antibodies did not interfere with the
induction of a booster response. Furthermore, this study shows
that detectable YF217D replication as evidenced by viraemia in
the week after vaccination, was not required for induction of a
booster response, which is consistent with previous findings by
Reinhardt et al. [23].
The enhanced efficiency of the i.d. route of vaccination may be
explained by direct targeting of antigen presenting cells (APCs) in
the dermis and epidermis. Despite the possibility of YF217D
replication in dendritic cells [24], Palmer and colleagues found this
replication to be restricted due to rapid processing of the virus
[25]. Together with the fact that despite the lower vaccine dose the
number of intradermally vaccinated participants in which
viraemia was measured was not reduced, it is likely that an even
more reduced vaccine dose (than fivefold reduction) administered
i.d. could induce a protective immune response.
The findings of this study have the following practical
implications: 1) in case of an outbreak of urban yellow fever or
vaccine shortage for travellers to endemic areas, i.d. administra-
tion of yellow fever vaccine will allow immunization of at least four
times as many individuals as s.c. vaccination with the same limited
vaccine supply, 2) provided that these results can be confirmed in
field studies in areas with potential yellow fever virus transmission,
the i.d. vaccination strategy could be implemented in routine
immunization programmes and support the ‘yellow fever risk
reduction initiative’ launched by the WHO and UNICEF to
envisage the immunization of 48 million people in 12 high-risk
countries between now and 2010 [26], 3) finally, these results
suggest that travellers with a possible history of egg allergy in
whom an i.d. test dose of 0?1 ml YF217D vaccine yielded a strong
local urticarial reaction do not need further vaccination, but this
should always be checked by virus neutralization tests.
Supporting Information
Checklist S1 CONSORT Checklist
Found at: doi:10.1371/journal.pone.0001993.s001 (0.07 MB
DOC)
Protocol S1 Trial Protocol
Found at: doi:10.1371/journal.pone.0001993.s002 (0.10 MB
DOC)
Protocol S2 Trial Protocol
Found at: doi:10.1371/journal.pone.0001993.s003 (0.03 MB
DOC)
Protocol S3 Trial Protocol
Found at: doi:10.1371/journal.pone.0001993.s004 (0.03 MB
DOC)
Protocol S4 Trial Protocol
Found at: doi:10.1371/journal.pone.0001993.s005 (0.03 MB
DOC)
Acknowledgments
The authors thank A. de Visser, H. el Bannoudi and C. Burghoorn-Maas
for their technical assistance in this study.
Author Contributions
Conceived and designed the experiments: AR. Performed the experiments:
AR. Analyzed the data: AR LV. Contributed reagents/materials/analysis
tools: AR AV PB. Wrote the paper: AR. Other: Contributed to analysis of
laboratory experiments: AV PB. Contributed to interpretation of the data:
Jv AV PB. Contributed to the drafting of the manuscript: Jv. Designed the
experiments and study: LV. Contributed to the writing of the paper: LV.
References
1. Robertson SE, Hull BP, Tomori O, Bele O, LeDuc JW, et al. (1996) Yellow
fever: a decade of reemergence. JAMA 276: 1157–1162.
2. Monath TP (2001) Yellow fever: an update. Lancet Infect Dis 1: 11–20.
3. WHO (2005) Weekly epidemiological record. Yellow fever situation in Africa
and South America. http://www.who.int/wer/2006/wer8133.pdf 81: 317–324.
Accessed 10 Oct 2007.
4. Roberts L (2007) Infectious disease. Resurgence of yellow fever in Africa
prompts a counterattack. Science 316: 1109.
5. Monath TP (1999) Yellow Fever. In: Plotkin SA, Orenstein WA, eds. Vaccines.
W.B. Saunders Company. pp 815–879.
6. Monath TP (1996) Stability of yellow fever vaccine. Dev Biol Stand 87: 219–225.
7. Belshe RB, Newman FK, Cannon J, Duane C, Treanor J, et al. (2004) Serum
antibody responses after intradermal vaccination against influenza. N Engl J Med
351: 2286–2294.
8. Kenney RT, Frech SA, Muenz LR, Villar CP, Glenn GM (2004) Dose sparing
with intradermal injection of influenza vaccine. N Engl J Med 351: 2295–2301.
9. Redfield RR, Innis BL, Scott RM, Cannon HG, Bancroft WH (1985) Clinical
evaluation of low-dose intradermally administered hepatitis B virus vaccine. A
cost reduction strategy. JAMA 254: 3203–3206.
10. Warrell MJ, Warrell DA, Suntharasamai P, Viravan C, Sinhaseni A, et al. (1983)
An economical regimen of human diploid cell strain anti-rabies vaccine for post
exposure prophylaxis. Lancet 2: 301–304.
11. Fox JP, Luty Kossobudski S, Fonseca da Cunha J (1943) Field studies on the
immune response to 17D yellow fever virus. Relation to virus substrain, dose and
route of inoculation. The American Journal of Hygiene 38: 113–138.
12. Cannon SA, Dewhurst F (1953) Vaccination by scarification with 17D yellow
fever vaccine prepared at Yaba, Lagos, Nigeria. Ann Trop Med Parasitol 47:
381–393.
13. Dick GW (1952) A preliminary evaluation of the immunizing power of chick-
embryo 17 D yellow fever vaccine inoculated by scarification. Am J Hyg 55:
140–153.
14. Center for Disease Control, Mantoux Tuberculosis Skin Test Facilitator Guide.
http://www.cdc.gov/tb/pubs/Mantoux/part1.htm (accessed 2nd of August 2007).
15. De Madrid AT, Porterfield JS (1969) A simple micro-culture method for the study
of group B arboviruses. Bulletin of the World Health Organization 40: 113–121.
16. Mason RA, Tauraso NM, Spertzel RO, Ginn RK (1873) Yellow fever vaccine:
direct challenge of monkeys given graded doses of 17D vaccine. Appl Microbiol
25: 539–544.
Intradermal YF-17D Vaccination
PLoS ONE | www.plosone.org 7 April 2008 | Volume 3 | Issue 4 | e1993
17. Nijhuis M, van Maarseveen N, Schuurman R, Verkuijlen S, de Vos M, et al.
(2002) Rapid and sensitive routine detection of all members of the genus
enterovirus in different clinical specimens by real-time PCR. J Clin Microbiol
40: 3666–3670.
18. Drosten C, Gottig S, Schilling S, Asper M, Panning M, et al. (2002) Rapid
detection and quantification of RNA of Ebola and Marburg viruses, Lassa virus,
Crimean-Congo hemorrhagic fever virus, Rift Valley fever virus, dengue virus,
and yellow fever virus by real-time reverse transcription-PCR. J Clin Microbiol
40: 2323–2330.
19. Armitage P, Berry G, Matthews J (2002) Statistical methods in medical research.
4 ed. Oxford: Blackwell Science.
20. World Health Organization Expert Committee on Biological Standardization.
46th report (1998) WHO Technical Report ser. No. 872. Geneva, World Health
Organization.
21. Monath TP (2005) Yellow Fever Vaccine. Exp rev vaccines 4: 553–574.
22. Dean CH, Alarcon JB, Waterston AM, Draper K, Early R, et al. (2005)
Cutaneous delivery of a live, attenuated chimeric flavivirus vaccine against
Japanese encephalitis (ChimeriVax)-JE) in non-human primates. Human Vaccin
1: 106–111.
23. Reinhardt B, Jaspert R, Niedrig M, Kostner C, L’age-Stehr J (1998)
Development of viremia and humoral and cellular parameters of immune
activation after vaccination with yellow fever virus strain 17D: a model of human
flavivirus infection. J Med Virol 56: 159–167.
24. Barba-Spaeth G, Longman RS, Albert ML, Rice CM (2005) Live attenuated
yellow fever 17D infects human DCs and allows for presentation of endogenous
and recombinant T cell epitopes. J Exp Med 202: 1179–1184.
25. Palmer DR, Fernandez S, Bisbing J, Peachman KK, Rao M, et al. (2007)
Restricted replication and lysosomal trafficking of yellow fever 17D vaccine virus
in human dendritic cells. J Gen Virol 88: 148–156.
26. WHO (2007) Weekly epidemiological record. Assessment of yellow fever
epidemic risk-a decision-making tool for preventive immunization campaigns.
http://www.who.int/wer/2007/wer8218.pdf. 82: 153–160.
Intradermal YF-17D Vaccination
PLoS ONE | www.plosone.org 8 April 2008 | Volume 3 | Issue 4 | e1993
